Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Accured Expenses (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Change in Accured Expenses for 3 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 19.93% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 35.06% year-over-year, with the annual reading at $5.1 million for FY2025, 35.06% up from the prior year.
  • Change in Accured Expenses hit $2.7 million in Q4 2025 for Compass Therapeutics, up from -$2.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q1 2025 to a low of -$4.3 million in Q3 2024.
  • Historically, Change in Accured Expenses has averaged -$25583.3 across 3 years, with a median of -$1.6 million in 2023.
  • Biggest YoY gain for Change in Accured Expenses was 1090.99% in 2025; the steepest drop was 141.06% in 2025.
  • Year by year, Change in Accured Expenses stood at -$3.1 million in 2023, then soared by 207.7% to $3.4 million in 2024, then fell by 19.93% to $2.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CMPX at $2.7 million in Q4 2025, -$2.3 million in Q3 2025, and -$2.2 million in Q2 2025.